VOLUME 34 : NUMBER 4 : August 2011
- About us
- Contact us
Medicines Safety Update is the medicines safety bulletin of the Therapeutic Goods Administration (TGA)
In this issue:
Cramps, quinine and thrombocytopenia
The TGA continues to receive reports of thrombocytopenia in people taking quinine to treat muscle cramps. Health professionals are reminded that quinine is not approved for the treatment of nocturnal cramps because of its low efficacy and the risk of thrombocytopenia. Non-pharmacological interventions, such as stretching, should be considered for preventing cramps.
In 2004, the Product Information (PI) for quinine tablets was amended and the indication for nocturnal cramps removed. Quinine tablets (Quinbisul, Quinate and Quinsul) are now only approved for treatment of malaria due to strains of Plasmodium falciparum resistant to chloroquine and the related 4-aminoquinolines.
Thrombocytopenia continues to be reported
Up to 2004, the TGA had received 228 reports of thrombocytopenia in people taking quinine, six of which were fatal.1 Since 2004, the TGA has received a further 21 reports of thrombocytopenia in people taking quinine, including several in the past few years (see table). In most cases, patients were prescribed quinine to treat leg cramps.
In 2010, a case reported to the TGA involved a 73-year-old woman who had been taking one quinine tablet every two days for muscle cramps for one year. She presented with a history of three days of bleeding gums, nose bleeding and multiple bruises and was found to have a platelet count of 4 x 109/L. Quinine was ceased and her platelet count recovered to normal.
Utilisation data show that although Pharmaceutical Benefits Scheme (PBS) prescribing of quinine has reduced substantially since removal of the indication and PBS listing for muscle cramps, private prescribing of quinine continues.2 It is likely that 'off label' prescribing for muscle cramps occurs.
Quinine is not approved for treatment of muscle cramps
When a patient presents with leg cramps, consideration should be given to non-pharmacological interventions for cramps such as stretching. An NPS factsheet describes suitable stretches for people who experience nocturnal cramps.3
|*to 2 June 2011|
Venlafaxine and stress cardiomyopathy
Published case reports have suggested that stress cardiomyopathy may be an adverse effect of venlafaxine. There is currently insufficient evidence to confirm an association, although a biologically plausible mechanism exists. Clinicians are reminded to report suspected adverse reactions of all types, even for drugs that have been available for many years.
Venlafaxine is a potent selective serotonin-noradrenaline reuptake inhibitor. It also exhibits rate-dependent sodium channel blocking activity. Venlafaxine is approved for the treatment of major depression, generalised anxiety disorder, social anxiety disorder and panic disorder, including prevention of relapse.
Features of stress cardiomyopathy
Stress cardiomyopathy, or Tako-Tsubo cardiomyopathy, is characterised by an acute transient left ventricular dysfunction with akinesia of the left ventricular apex and a hypercontractile base, occurring predominantly in women in the context of emotional distress.1 Accompanying transient electrocardiographic changes may mimic an acute coronary syndrome. It is thought the findings are due to catecholaminemediated neurogenic myocardial stunning caused by emotional stress. Elevated plasma catecholamines are a typical finding.
Following a literature report1 and routine pharmacovigilance activities, the TGA has undertaken a review of stress cardiomyopathy in association with venlafaxine use. To March 2011, the TGA had received three case reports of stress cardiomyopathy in patients taking venlafaxine: one in the context of overdose, and two in patients over the age of 70 with normal dosing. All three cases had the diagnosis confirmed with echocardiography and noradrenaline levels. For the same time period there were six other cases of cardiomyopathy and one case of cardiac failure reported in patients taking venlafaxine. These numbers are very small in the context of use of venlafaxine in Australia. Approximately 21 million PBS prescriptions for venlafaxine have been dispensed.
Two additional cases of stress cardiomyopathy in patients taking venlafaxine, both in the context of overdose, are identified in the database of the World Health Organization's Programme for International Drug Monitoring. Thirty-nine patients were reported to have a cardiomyopathy, nine had congestive cardiomyopathy, and 58 patients had cardiac failure in association with venlafaxine use. The WHO database provides insufficient information about the diagnosis and features of the reported cases of cardiomyopathy to confirm an underlying causal relationship beyond a temporal association.*
By increasing plasma catecholamine levels, possibly by the inhibition of noradrenaline reuptake, a potential mechanism exists for venlafaxine to cause stress cardiomyopathy.
The PI states that venlafaxine causes a dose-related increase in resting heart rate and is associated with hypertension and increased serum cholesterol, which are presumed to be additive to other cardiovascular risk factors, and that venlafaxine should be used with caution in patients with unstable heart disease.2 In these patients, assessment of the cardiovascular system (e.g. ECG, serum electrolytes during diuretic treatment) should be considered during treatment with venlafaxine, particularly when the dose is increased beyond 150–200 mg daily.
The TGA continues to monitor the potential association between venlafaxine and stress cardiomyopathy. Clinicians are reminded to report all adverse events that are potentially medication-related.
*The information in adverse event reports in the WHO database is not homogeneous with respect to the sources of the information or the likelihood that the pharmaceutical product caused the suspected adverse reaction. The information in this article does not represent the opinion of the WHO.
In utero antipsychotic exposure and neonatal extrapyramidal and withdrawal adverse effects
Neonates exposed to antipsychotic medications during the third trimester of pregnancy may be at risk of experiencing extrapyramidal signs and/or withdrawal symptoms. Neonatal drug withdrawal symptoms may occur when drug exposure ceases at birth. All registered antipsychotics are now classified as Australian pregnancy category C.
The safety of antipsychotic use in pregnancy and lactation has not been thoroughly studied. The antenatal management of serious mental illnesses, such as schizophrenia and bipolar affective disorder, involves clinical decision-making about the continuation, commencement or discontinuation of psychotropic treatments. If the use of an antipsychotic in a pregnant woman is clinically indicated, avoid unnecessarily high doses and duration of treatment.1 The decision about using antipsychotics should be made on a case-by-case basis, taking into account the woman's individual characteristics, her mental health history and tendency to relapse, the risk to the fetus or infant, and the risk – to both mother and fetus – of not treating the disorder.2
The potential risks to the fetus or infant from antipsychotic exposure include structural teratogenicity, pregnancy complications (e.g. inducing maternal diabetes), effects on fetal growth, neonatal toxicity/withdrawal and long-term adverse neurodevelopmental outcomes. There is growing evidence that psychiatric disorders themselves appear to independently elevate the risk of spontaneous abortion, pre-eclampsia, premature birth, low birth weight, smaller head circumference and long-term adverse neurodevelopment.13
When used in pregnancy, many typical antipsychotics are known to be associated with the development of reversible extrapyramidal signs (EPS), such as dyskinetic movements, in the neonate. Although the incidence of EPS tends to be lower in patients treated with some atypical antipsychotics, this may not necessarily translate to a lower risk to neonates exposed in utero . Fetal exposure is largely dependent on placental transfer which can vary depending on the placental permeability of different antipsychotics. Spontaneous adverse event reporting provides evidence of both EPS and withdrawal symptoms occurring in the neonate following chronic in utero exposure to atypical antipsychotics.
To May 2011, the TGA had received 19 reports of EPS or withdrawal symptoms in neonates. Of these, an atypical antipsychotic was suspected in 18 reports. Many reported cases were confounded by concomitant use of other psychotropic medication (e.g. antidepressants), obstetric complications (e.g. fetal distress) or tobacco and alcohol exposure. However an antipsychotic alone was suspected in four reports.
In the cases reported to the TGA, adverse events included jitteriness, agitation, tremor, feeding problems, somnolence, breathing difficulties, hypertonia, hypotonia, pronounced startle reflex and myoclonus. Although the term 'neonatal drug withdrawal' was specifically identified in 14 reports, it was not possible to definitively determine whether these were related directly to antipsychotic toxicity or to withdrawal. Reported time to onset ranged from birth to seven days. Where outcome was described, most neonates recovered within a few days although some required supportive therapy and prolonged hospitalisation. An analysis of adverse events reported in the United States described similar findings.4
Changes to PI for antipsychotics
PI documents for all antipsychotics are being updated with warnings about neonatal EPS and withdrawal symptoms. All registered antipsychotics are Australian pregnancy category C. Category C refers to: 'Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.'
See below for information about the TGA's new 'Prescribing medicines in pregnancy' database.
Prescribing medicines in pregnancy – new TGA database
As part of the recent website upgrade, the TGA has developed a new, searchable database for use by health professionals prescribing medicines to pregnant women. The database can be found at www.tga.gov.au/hp/medicines-pregnancy.htm.
The 'Prescribing medicines in pregnancy' database replaces the booklet 'Prescribing medicines in pregnancy – an Australian categorisation of the risk of drug use in pregnancy'. The booklet was first published in 1989, with the latest edition published in 1999, and subsequent updates added as amendments on the TGA website. Unlike the booklet, the new database is searchable by generic name (or part of the generic name), and by classification using a drop-down list.
Once the user finds the relevant medicine, clicking on the medicine name will display the pregnancy category, an explanation of the category and, if available, a safety statement specific for the medicine or medicine group (see figure).
The database contains over 1200 individual entries, including all new medicines and any changes of pregnancy category for existing medicines. A separate page lists the therapeutic goods exempted from pregnancy classification.
Other pages on the TGA website with information relevant to prescribing medicines in pregnancy include the PI documents (www.ebs.tga.gov.au) and the Australian Public Assessment Reports (www.tga.gov.au/industry/pm-auspar.htm).
|What to report? You don't need
to be certain, just suspicious!
|The TGA encourages the reporting of all
suspected adverse reactions to medicines, including
vaccines, over-the-counter medicines, herbal, traditional or
alternative remedies. We particularly request reports of:
||Reports may be submitted:
Medicines Safety Update is aimed at health professionals. It is intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicines Safety Update is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete, and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2015.
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or email@example.com.